INTRODUCTION
Pulmonary embolism (PE) is one of the leading cardiovascular causes of morbidity and mortality in patients surviving an acute coronary syndrome or stroke, and a large number of these patients die even before the diagnosis, due to the ambiguous forms of clinical presentation and lack of highly specific signs and symptoms. 1, 2 An important percent of these patients remains undiagnosed until the chronic phase of the disease, when pulmonary hypertension is installed, or in other cases, during autopsy. 3, 4 Large registry studies show that approximately 10% of PE patients die during the first three months after diagnosis. 5, 6 The early recognition and treatment of PE is essential, as many studies demonstrated that mortality rates drop significantly if adequate therapy is administered from the early stages. The clinical setting of PE patients is also an important factor for both short-and long-term survival. The 30-day mortality rates vary from 1% to over 50%, mainly depending on the baseline clinical characteristics of the patients. 10 Those presenting in the emergency department (ED) with hemodynamic instability, right ventricular dysfunction, or necessitating cardiopulmonary resuscitation have mortality rates up to 70-80% in the acute phase.
for higher long-term mortality rates. 11 The widespread use noninvasive diagnostic tools in the ED have led to better accuracy in the identification of even lower risk patients.
The aim of this update is to summarize the various patterns of PE presentations in the ED.
PE IN THE EmERgENCY DEPARTmENT
The diagnosis of PE can be a very challenging task in the ED due to the diverse, common, and unspecific symptoms. 13 The validated clinical probability scores and biomarkers help the ED physician to select the proper patient category who should undergo further investigations, as undiagnosed PE leads to high mortality rates, and unnecessary examinations create high costs and a possibly faulty diagnosis.
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CLINICAL PROBABILITY AND RISk STRATIfICATION
Although the common symptoms and signs in PE are limited in sensitivity and specificity, clinical judgment, aided by the use of prediction scores, can provide a distribution of patients with suspected PE into specific categories of probability. 22 Through these scores, the algorithm sequence of predicting diagnosis will be based on binary decisions, thus inappropriate variance of clinical decision will be confined. 22 The sequence of diagnostic work-up consist of applying pre-test probability rules, which are necessary in determining whether further invasive or noninvasive investigations are needed. There are several pre-test scores being used, either to rule-in or to rule-out PE diagnosis.
The most applied validated pre-test scores are: the Geneva score with two derived models, the Wells score, the PISA models, the Charcotte model, the PESI scores, and the Gestalt model.
The original Geneva model (Wicki criteria) of risk strat-
ification is based on assessment at the time of presentation. Similar to original Geneva score are the revised Geneva score and the simplified Geneva score. 23 Nowadays, the revised Geneva Criteria are most used in determining PE probability risk. 24 Patients presenting a total score equal or less than 2 points are considered unlikely to have PE. 25 Another widely used probability risk score of PE is the In order to assess the mortality and the adverse medical events in PE patients, the Pulmonary Embolism Severity Index (PESI) and the simplified PESI (sPESI) were introduced and validated. 30 The PESI stratifies patients in five risk classes corresponding to the 30-day mortality rate.
The sPESI includes only 6 clinical factors, namely age over 80 years, malignancy, chronic cardiopulmonary disease, heart rate >110 bpm, systolic blood pressure <100 mm Hg, and SaO2 <90%. If one of these parameters is present, a high risk of 30-day mortality and adverse events is associated. 31 Current guidelines recommend the assessment of the PESI score at hospital admission and initiation of thrombolytic therapy.
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SYNCOPE IN PE
Until recently, syncope was considered an uncommon clinical presentation for PE, and current guidelines and recommendations do not focus enough on the consideration and work-up of PE for these patients. However, in a recent, highly cited publication, Prandoni et al. identified a much higher prevalence (17.3%) of PE in patients presenting in the ED for a first episode of syncope. 32 Based on
Prandoni's results, Oqab et al. performed a meta-analysis which included 6,608 patients from ED and found significantly lower prevalence of PE (p <0.0001) in the same category of patients. 33 In a recent paper published by Frizell et al., the results of the Prandoni study are also contested, as only 1.4% of patients were identified with PE from a total number of 348 of patients presenting with syncope in the ED. 34 These controverting results suggest the need of further investigations for the determination of the prevalence of PE in patients presenting with syncope in the ED.
UNUSUAL PRESENTATIONS Of PE IN OUR ExPERIENCE
Unusual presentations of PE can be frequently encountered in the ED. We report, for instance, the case of a pa- In order to investigate the cause of the thrombotic events which lead to PE, it is important to consider other rare conditions in patients with unclear clinical presentation. Literature data shows that the acquired hypercoagulability status emphasized by a thrombotic event can be caused by APLS with an incidence of up to 2% in the general population and can consist in a hypercoagulability state with high implications in the cardiovascular system, with a 5-year mortality rate of 5.3%. [35] [36] [37] [38] [39] These patients are at high risk of developing arterial or venous thrombosis, intracardiac thrombus, pulmonary hypertension, coronary artery diseases, valvular disease, and stroke, and also can determine fetal loss. 40, 41 The association between atrial fibrillation and PE is still 
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